OasisLMS

This study examined outcomes of patients with atrial fibrillation treated with pulsed field ablation (PFA) and found a notably high incidence of phrenic nerve injury during the procedure. Most injuries were transient, but some persisted beyond the immediate peri-procedural period, raising concerns about long-term safety. The findings highlight the need for refined techniques and monitoring strategies to mitigate phrenic nerve injury risk with PFA.

Please join host Michael S. Lloyd, MD, FHRS as he discusses the finding of this study with his guests Andrea M. Russo, MD, FHRS and Birju Rao, MD, Msci in Atlanta at the HRX Live 2025 conference.

• Examine outcomes of patients with atrial fibrillation treated with pulsed field ablation (PFA).

Article Authors

Louis Chéhirlian, MD, Linda Koutbi, MD, Julien Mancini, MD, PhD, Jérôme Hourdain, MD, Robin Richard-Vitton, MD, Marie Wilkin, MD, Jean-Claude Deharo, MD, Baptiste Maille, MD, PhD, Frédéric Franceschi, MD, PhD 

Podcast Contributors

Michael S. Lloyd, MD, FHRS | Emory University
Andrea M. Russo, MD, FHRS | Cooper University Health Care
Birju Rao, MD, Msci | Emory University

All relevant financial relationships have been mitigated.

Host Disclosure(s):

M. Lloyd:  

•Membership on Advisory Committees: Boston Scientific
•Speaking/Teaching/Consulting: Medtronic, ArgaMedtech, Circa Scientific

​Contributor Disclosure(s): 
 
B. Rao

•Nothing relevant to disclose.

A. Russo:

•Honoraria/Speaking/Consulting: Pacemate, Abbott Medical, Medtronic, BiosenseWebster, Inc., AtriCure, Inc., Bayer Healthcare Pharmaceuticals, Boston Scientific
•Research: Medtronic, Boston Scientific, Abbott, Bayer Healthcare Pharmaceuticals
•Royalty Income: UpToDate,Inc.
•Fellowship Support: Medtronic, Inc.

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.